Prebiotics protect against acute graft-versus-host disease and preserve the gut microbiota in stem cell transplantation
Acute graft-versus-host disease (aGVHD) is a major cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Therefore, management of aGVHD is important for successful transplantation. Mucosal damage and alteration of the gut microbiota after allo-HSCT ar...
Gespeichert in:
Veröffentlicht in: | Blood advances 2020-10, Vol.4 (19), p.4607-4617 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 4617 |
---|---|
container_issue | 19 |
container_start_page | 4607 |
container_title | Blood advances |
container_volume | 4 |
creator | Yoshifuji, Kota Inamoto, Kyoko Kiridoshi, Yuko Takeshita, Kozue Sasajima, Satoshi Shiraishi, Yukiko Yamashita, Yuko Nisaka, Yuko Ogura, Yukari Takeuchi, Rie Toya, Takashi Igarashi, Aiko Najima, Yuho Doki, Noriko Kobayashi, Takeshi Ohashi, Kazuteru Suda, Wataru Atarashi, Koji Shiota, Atsushi Hattori, Masahira Honda, Kenya Kakihana, Kazuhiko |
description | Acute graft-versus-host disease (aGVHD) is a major cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Therefore, management of aGVHD is important for successful transplantation. Mucosal damage and alteration of the gut microbiota after allo-HSCT are key factors in the development of aGVHD. We conducted a prospective study to evaluate the ability of prebiotics, which can alleviate mucosal damage and manipulate the gut microbiota, to mitigate posttransplantation complications, including aGVHD. Resistant starch (RS) and a commercially available prebiotics mixture, GFO, were administered to allo-HSCT recipients from pretransplantation conditioning to day 28 after allo-HSCT. Prebiotic intake mitigated mucosal injury and reduced the incidence of all aGVHD grades combined and of aGVHD grades 2 to 4. The cumulative incidence of skin aGVHD was markedly decreased by prebiotics intake. Furthermore, the gut microbial diversity was well maintained and butyrate-producing bacterial population were preserved by prebiotics intake. In addition, the posttransplantation fecal butyrate concentration was maintained or increased more frequently in the prebiotics group. These observations indicate that prebiotic intake may be an effective strategy for preventing aGVHD in allo-HSCT, thereby improving treatment outcomes and the clinical utility of stem cell transplantation approaches. This study was registered on the University Hospital Medical Information Network (UMIN) clinical trials registry (https://www.umin.ac.jp/ctr/index.htm) as #UMIN000027563.
•The intake of probiotics shortened the duration of oral mucositis and diarrhea, and reduced the incidence and severity of aGVHD.•The microbial diversity, population of butyrate producers, and butyrate concentration were maintained in patients who consumed prebiotics.
[Display omitted] |
doi_str_mv | 10.1182/bloodadvances.2020002604 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7556149</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S2473952920311939</els_id><sourcerecordid>2447547968</sourcerecordid><originalsourceid>FETCH-LOGICAL-c629t-2b92a4a8a2ba8285516fda3fc644fbe03f14a0bb05f8be4961164cf354f92d893</originalsourceid><addsrcrecordid>eNqFkU9v1DAQxSMEolXpV0A-ckmxHeePL0hQUUCqBAc4WxNnvGuU2IvHCeLb49WWhZ44jWX_3pvxvKpigt8IMcjX4xzjBNMGwSLdSC4557Lj6kl1KVXf1Lpt-qfns9QX1TXR9wKJvmtaLZ9XF43UWvSSX1Y_vyQcfczeEjukmNFmBjvwgUq1a0a2S-ByvWGilep9LPeTJwRCBmEqGiRMG7K8L-ia2eJtikdHYD4wyrgwi_PMcoJAhxlChuxjeFE9czATXj_Uq-rb3fuvtx_r-88fPt2-va9tJ3Wu5aglKBhAjjDIoW1F5yZonO2UciPyxgkFfBx564YRle6E6JR1TaucltOgm6vqzcn3sI4LThZDGWQ2h-QXSL9MBG8evwS_N7u4mb5tO6GOBq8eDFL8sSJls3g6_ggCxpWMVKpvVa-7oaDDCS0bIErozm0EN8fozKPozN_oivTlv2OehX-CKsC7E4BlWZvHZMh6LDaTTyUzM0X__y6_AWVGtCw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2447547968</pqid></control><display><type>article</type><title>Prebiotics protect against acute graft-versus-host disease and preserve the gut microbiota in stem cell transplantation</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Yoshifuji, Kota ; Inamoto, Kyoko ; Kiridoshi, Yuko ; Takeshita, Kozue ; Sasajima, Satoshi ; Shiraishi, Yukiko ; Yamashita, Yuko ; Nisaka, Yuko ; Ogura, Yukari ; Takeuchi, Rie ; Toya, Takashi ; Igarashi, Aiko ; Najima, Yuho ; Doki, Noriko ; Kobayashi, Takeshi ; Ohashi, Kazuteru ; Suda, Wataru ; Atarashi, Koji ; Shiota, Atsushi ; Hattori, Masahira ; Honda, Kenya ; Kakihana, Kazuhiko</creator><creatorcontrib>Yoshifuji, Kota ; Inamoto, Kyoko ; Kiridoshi, Yuko ; Takeshita, Kozue ; Sasajima, Satoshi ; Shiraishi, Yukiko ; Yamashita, Yuko ; Nisaka, Yuko ; Ogura, Yukari ; Takeuchi, Rie ; Toya, Takashi ; Igarashi, Aiko ; Najima, Yuho ; Doki, Noriko ; Kobayashi, Takeshi ; Ohashi, Kazuteru ; Suda, Wataru ; Atarashi, Koji ; Shiota, Atsushi ; Hattori, Masahira ; Honda, Kenya ; Kakihana, Kazuhiko</creatorcontrib><description>Acute graft-versus-host disease (aGVHD) is a major cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Therefore, management of aGVHD is important for successful transplantation. Mucosal damage and alteration of the gut microbiota after allo-HSCT are key factors in the development of aGVHD. We conducted a prospective study to evaluate the ability of prebiotics, which can alleviate mucosal damage and manipulate the gut microbiota, to mitigate posttransplantation complications, including aGVHD. Resistant starch (RS) and a commercially available prebiotics mixture, GFO, were administered to allo-HSCT recipients from pretransplantation conditioning to day 28 after allo-HSCT. Prebiotic intake mitigated mucosal injury and reduced the incidence of all aGVHD grades combined and of aGVHD grades 2 to 4. The cumulative incidence of skin aGVHD was markedly decreased by prebiotics intake. Furthermore, the gut microbial diversity was well maintained and butyrate-producing bacterial population were preserved by prebiotics intake. In addition, the posttransplantation fecal butyrate concentration was maintained or increased more frequently in the prebiotics group. These observations indicate that prebiotic intake may be an effective strategy for preventing aGVHD in allo-HSCT, thereby improving treatment outcomes and the clinical utility of stem cell transplantation approaches. This study was registered on the University Hospital Medical Information Network (UMIN) clinical trials registry (https://www.umin.ac.jp/ctr/index.htm) as #UMIN000027563.
•The intake of probiotics shortened the duration of oral mucositis and diarrhea, and reduced the incidence and severity of aGVHD.•The microbial diversity, population of butyrate producers, and butyrate concentration were maintained in patients who consumed prebiotics.
[Display omitted]</description><identifier>ISSN: 2473-9529</identifier><identifier>EISSN: 2473-9537</identifier><identifier>DOI: 10.1182/bloodadvances.2020002604</identifier><identifier>PMID: 32991720</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Gastrointestinal Microbiome ; Graft vs Host Disease - prevention & control ; Hematopoietic Stem Cell Transplantation ; Humans ; Prebiotics ; Prospective Studies ; Transplantation</subject><ispartof>Blood advances, 2020-10, Vol.4 (19), p.4607-4617</ispartof><rights>2020 American Society of Hematology</rights><rights>2020 by The American Society of Hematology.</rights><rights>2020 by The American Society of Hematology 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c629t-2b92a4a8a2ba8285516fda3fc644fbe03f14a0bb05f8be4961164cf354f92d893</citedby><cites>FETCH-LOGICAL-c629t-2b92a4a8a2ba8285516fda3fc644fbe03f14a0bb05f8be4961164cf354f92d893</cites><orcidid>0000-0001-5422-0736 ; 0000-0002-7436-972X ; 0000-0001-5062-5795 ; 0000-0002-2861-9724</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7556149/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7556149/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,864,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32991720$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yoshifuji, Kota</creatorcontrib><creatorcontrib>Inamoto, Kyoko</creatorcontrib><creatorcontrib>Kiridoshi, Yuko</creatorcontrib><creatorcontrib>Takeshita, Kozue</creatorcontrib><creatorcontrib>Sasajima, Satoshi</creatorcontrib><creatorcontrib>Shiraishi, Yukiko</creatorcontrib><creatorcontrib>Yamashita, Yuko</creatorcontrib><creatorcontrib>Nisaka, Yuko</creatorcontrib><creatorcontrib>Ogura, Yukari</creatorcontrib><creatorcontrib>Takeuchi, Rie</creatorcontrib><creatorcontrib>Toya, Takashi</creatorcontrib><creatorcontrib>Igarashi, Aiko</creatorcontrib><creatorcontrib>Najima, Yuho</creatorcontrib><creatorcontrib>Doki, Noriko</creatorcontrib><creatorcontrib>Kobayashi, Takeshi</creatorcontrib><creatorcontrib>Ohashi, Kazuteru</creatorcontrib><creatorcontrib>Suda, Wataru</creatorcontrib><creatorcontrib>Atarashi, Koji</creatorcontrib><creatorcontrib>Shiota, Atsushi</creatorcontrib><creatorcontrib>Hattori, Masahira</creatorcontrib><creatorcontrib>Honda, Kenya</creatorcontrib><creatorcontrib>Kakihana, Kazuhiko</creatorcontrib><title>Prebiotics protect against acute graft-versus-host disease and preserve the gut microbiota in stem cell transplantation</title><title>Blood advances</title><addtitle>Blood Adv</addtitle><description>Acute graft-versus-host disease (aGVHD) is a major cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Therefore, management of aGVHD is important for successful transplantation. Mucosal damage and alteration of the gut microbiota after allo-HSCT are key factors in the development of aGVHD. We conducted a prospective study to evaluate the ability of prebiotics, which can alleviate mucosal damage and manipulate the gut microbiota, to mitigate posttransplantation complications, including aGVHD. Resistant starch (RS) and a commercially available prebiotics mixture, GFO, were administered to allo-HSCT recipients from pretransplantation conditioning to day 28 after allo-HSCT. Prebiotic intake mitigated mucosal injury and reduced the incidence of all aGVHD grades combined and of aGVHD grades 2 to 4. The cumulative incidence of skin aGVHD was markedly decreased by prebiotics intake. Furthermore, the gut microbial diversity was well maintained and butyrate-producing bacterial population were preserved by prebiotics intake. In addition, the posttransplantation fecal butyrate concentration was maintained or increased more frequently in the prebiotics group. These observations indicate that prebiotic intake may be an effective strategy for preventing aGVHD in allo-HSCT, thereby improving treatment outcomes and the clinical utility of stem cell transplantation approaches. This study was registered on the University Hospital Medical Information Network (UMIN) clinical trials registry (https://www.umin.ac.jp/ctr/index.htm) as #UMIN000027563.
•The intake of probiotics shortened the duration of oral mucositis and diarrhea, and reduced the incidence and severity of aGVHD.•The microbial diversity, population of butyrate producers, and butyrate concentration were maintained in patients who consumed prebiotics.
[Display omitted]</description><subject>Gastrointestinal Microbiome</subject><subject>Graft vs Host Disease - prevention & control</subject><subject>Hematopoietic Stem Cell Transplantation</subject><subject>Humans</subject><subject>Prebiotics</subject><subject>Prospective Studies</subject><subject>Transplantation</subject><issn>2473-9529</issn><issn>2473-9537</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkU9v1DAQxSMEolXpV0A-ckmxHeePL0hQUUCqBAc4WxNnvGuU2IvHCeLb49WWhZ44jWX_3pvxvKpigt8IMcjX4xzjBNMGwSLdSC4557Lj6kl1KVXf1Lpt-qfns9QX1TXR9wKJvmtaLZ9XF43UWvSSX1Y_vyQcfczeEjukmNFmBjvwgUq1a0a2S-ByvWGilep9LPeTJwRCBmEqGiRMG7K8L-ia2eJtikdHYD4wyrgwi_PMcoJAhxlChuxjeFE9czATXj_Uq-rb3fuvtx_r-88fPt2-va9tJ3Wu5aglKBhAjjDIoW1F5yZonO2UciPyxgkFfBx564YRle6E6JR1TaucltOgm6vqzcn3sI4LThZDGWQ2h-QXSL9MBG8evwS_N7u4mb5tO6GOBq8eDFL8sSJls3g6_ggCxpWMVKpvVa-7oaDDCS0bIErozm0EN8fozKPozN_oivTlv2OehX-CKsC7E4BlWZvHZMh6LDaTTyUzM0X__y6_AWVGtCw</recordid><startdate>20201013</startdate><enddate>20201013</enddate><creator>Yoshifuji, Kota</creator><creator>Inamoto, Kyoko</creator><creator>Kiridoshi, Yuko</creator><creator>Takeshita, Kozue</creator><creator>Sasajima, Satoshi</creator><creator>Shiraishi, Yukiko</creator><creator>Yamashita, Yuko</creator><creator>Nisaka, Yuko</creator><creator>Ogura, Yukari</creator><creator>Takeuchi, Rie</creator><creator>Toya, Takashi</creator><creator>Igarashi, Aiko</creator><creator>Najima, Yuho</creator><creator>Doki, Noriko</creator><creator>Kobayashi, Takeshi</creator><creator>Ohashi, Kazuteru</creator><creator>Suda, Wataru</creator><creator>Atarashi, Koji</creator><creator>Shiota, Atsushi</creator><creator>Hattori, Masahira</creator><creator>Honda, Kenya</creator><creator>Kakihana, Kazuhiko</creator><general>Elsevier Inc</general><general>American Society of Hematology</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-5422-0736</orcidid><orcidid>https://orcid.org/0000-0002-7436-972X</orcidid><orcidid>https://orcid.org/0000-0001-5062-5795</orcidid><orcidid>https://orcid.org/0000-0002-2861-9724</orcidid></search><sort><creationdate>20201013</creationdate><title>Prebiotics protect against acute graft-versus-host disease and preserve the gut microbiota in stem cell transplantation</title><author>Yoshifuji, Kota ; Inamoto, Kyoko ; Kiridoshi, Yuko ; Takeshita, Kozue ; Sasajima, Satoshi ; Shiraishi, Yukiko ; Yamashita, Yuko ; Nisaka, Yuko ; Ogura, Yukari ; Takeuchi, Rie ; Toya, Takashi ; Igarashi, Aiko ; Najima, Yuho ; Doki, Noriko ; Kobayashi, Takeshi ; Ohashi, Kazuteru ; Suda, Wataru ; Atarashi, Koji ; Shiota, Atsushi ; Hattori, Masahira ; Honda, Kenya ; Kakihana, Kazuhiko</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c629t-2b92a4a8a2ba8285516fda3fc644fbe03f14a0bb05f8be4961164cf354f92d893</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Gastrointestinal Microbiome</topic><topic>Graft vs Host Disease - prevention & control</topic><topic>Hematopoietic Stem Cell Transplantation</topic><topic>Humans</topic><topic>Prebiotics</topic><topic>Prospective Studies</topic><topic>Transplantation</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yoshifuji, Kota</creatorcontrib><creatorcontrib>Inamoto, Kyoko</creatorcontrib><creatorcontrib>Kiridoshi, Yuko</creatorcontrib><creatorcontrib>Takeshita, Kozue</creatorcontrib><creatorcontrib>Sasajima, Satoshi</creatorcontrib><creatorcontrib>Shiraishi, Yukiko</creatorcontrib><creatorcontrib>Yamashita, Yuko</creatorcontrib><creatorcontrib>Nisaka, Yuko</creatorcontrib><creatorcontrib>Ogura, Yukari</creatorcontrib><creatorcontrib>Takeuchi, Rie</creatorcontrib><creatorcontrib>Toya, Takashi</creatorcontrib><creatorcontrib>Igarashi, Aiko</creatorcontrib><creatorcontrib>Najima, Yuho</creatorcontrib><creatorcontrib>Doki, Noriko</creatorcontrib><creatorcontrib>Kobayashi, Takeshi</creatorcontrib><creatorcontrib>Ohashi, Kazuteru</creatorcontrib><creatorcontrib>Suda, Wataru</creatorcontrib><creatorcontrib>Atarashi, Koji</creatorcontrib><creatorcontrib>Shiota, Atsushi</creatorcontrib><creatorcontrib>Hattori, Masahira</creatorcontrib><creatorcontrib>Honda, Kenya</creatorcontrib><creatorcontrib>Kakihana, Kazuhiko</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Blood advances</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yoshifuji, Kota</au><au>Inamoto, Kyoko</au><au>Kiridoshi, Yuko</au><au>Takeshita, Kozue</au><au>Sasajima, Satoshi</au><au>Shiraishi, Yukiko</au><au>Yamashita, Yuko</au><au>Nisaka, Yuko</au><au>Ogura, Yukari</au><au>Takeuchi, Rie</au><au>Toya, Takashi</au><au>Igarashi, Aiko</au><au>Najima, Yuho</au><au>Doki, Noriko</au><au>Kobayashi, Takeshi</au><au>Ohashi, Kazuteru</au><au>Suda, Wataru</au><au>Atarashi, Koji</au><au>Shiota, Atsushi</au><au>Hattori, Masahira</au><au>Honda, Kenya</au><au>Kakihana, Kazuhiko</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prebiotics protect against acute graft-versus-host disease and preserve the gut microbiota in stem cell transplantation</atitle><jtitle>Blood advances</jtitle><addtitle>Blood Adv</addtitle><date>2020-10-13</date><risdate>2020</risdate><volume>4</volume><issue>19</issue><spage>4607</spage><epage>4617</epage><pages>4607-4617</pages><issn>2473-9529</issn><eissn>2473-9537</eissn><abstract>Acute graft-versus-host disease (aGVHD) is a major cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Therefore, management of aGVHD is important for successful transplantation. Mucosal damage and alteration of the gut microbiota after allo-HSCT are key factors in the development of aGVHD. We conducted a prospective study to evaluate the ability of prebiotics, which can alleviate mucosal damage and manipulate the gut microbiota, to mitigate posttransplantation complications, including aGVHD. Resistant starch (RS) and a commercially available prebiotics mixture, GFO, were administered to allo-HSCT recipients from pretransplantation conditioning to day 28 after allo-HSCT. Prebiotic intake mitigated mucosal injury and reduced the incidence of all aGVHD grades combined and of aGVHD grades 2 to 4. The cumulative incidence of skin aGVHD was markedly decreased by prebiotics intake. Furthermore, the gut microbial diversity was well maintained and butyrate-producing bacterial population were preserved by prebiotics intake. In addition, the posttransplantation fecal butyrate concentration was maintained or increased more frequently in the prebiotics group. These observations indicate that prebiotic intake may be an effective strategy for preventing aGVHD in allo-HSCT, thereby improving treatment outcomes and the clinical utility of stem cell transplantation approaches. This study was registered on the University Hospital Medical Information Network (UMIN) clinical trials registry (https://www.umin.ac.jp/ctr/index.htm) as #UMIN000027563.
•The intake of probiotics shortened the duration of oral mucositis and diarrhea, and reduced the incidence and severity of aGVHD.•The microbial diversity, population of butyrate producers, and butyrate concentration were maintained in patients who consumed prebiotics.
[Display omitted]</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>32991720</pmid><doi>10.1182/bloodadvances.2020002604</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0001-5422-0736</orcidid><orcidid>https://orcid.org/0000-0002-7436-972X</orcidid><orcidid>https://orcid.org/0000-0001-5062-5795</orcidid><orcidid>https://orcid.org/0000-0002-2861-9724</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2473-9529 |
ispartof | Blood advances, 2020-10, Vol.4 (19), p.4607-4617 |
issn | 2473-9529 2473-9537 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7556149 |
source | MEDLINE; DOAJ Directory of Open Access Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central; Alma/SFX Local Collection |
subjects | Gastrointestinal Microbiome Graft vs Host Disease - prevention & control Hematopoietic Stem Cell Transplantation Humans Prebiotics Prospective Studies Transplantation |
title | Prebiotics protect against acute graft-versus-host disease and preserve the gut microbiota in stem cell transplantation |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T23%3A12%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prebiotics%20protect%20against%20acute%20graft-versus-host%20disease%20and%20preserve%20the%20gut%20microbiota%20in%20stem%20cell%20transplantation&rft.jtitle=Blood%20advances&rft.au=Yoshifuji,%20Kota&rft.date=2020-10-13&rft.volume=4&rft.issue=19&rft.spage=4607&rft.epage=4617&rft.pages=4607-4617&rft.issn=2473-9529&rft.eissn=2473-9537&rft_id=info:doi/10.1182/bloodadvances.2020002604&rft_dat=%3Cproquest_pubme%3E2447547968%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2447547968&rft_id=info:pmid/32991720&rft_els_id=S2473952920311939&rfr_iscdi=true |